These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8611732)
21. Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. Moretta A; Vitale M; Sivori S; Bottino C; Morelli L; Augugliaro R; Barbaresi M; Pende D; Ciccone E; Lopez-Botet M; Moretta L J Exp Med; 1994 Aug; 180(2):545-55. PubMed ID: 8046333 [TBL] [Abstract][Full Text] [Related]
22. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. Moretta A; Sivori S; Vitale M; Pende D; Morelli L; Augugliaro R; Bottino C; Moretta L J Exp Med; 1995 Sep; 182(3):875-84. PubMed ID: 7650491 [TBL] [Abstract][Full Text] [Related]
23. CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Sivori S; Vitale M; Bottino C; Marcenaro E; Sanseverino L; Parolini S; Moretta L; Moretta A Eur J Immunol; 1996 Oct; 26(10):2487-92. PubMed ID: 8898964 [TBL] [Abstract][Full Text] [Related]
24. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Vallera DA; Taylor PA; Sprent J; Blazar BR Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058 [TBL] [Abstract][Full Text] [Related]
25. General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. Ciccone E; Pende D; Nanni L; Di Donato C; Viale O; Beretta A; Vitale M; Sivori S; Moretta A; Moretta L Int Immunol; 1995 Mar; 7(3):393-400. PubMed ID: 7794819 [TBL] [Abstract][Full Text] [Related]
27. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection. Held W; Cado D; Raulet DH J Exp Med; 1996 Nov; 184(5):2037-41. PubMed ID: 8920892 [TBL] [Abstract][Full Text] [Related]
28. Human NK cells and their receptors. Moretta L; Biassoni R; Bottino C; Cantoni C; Pende D; Mingari MC; Moretta A Microbes Infect; 2002 Dec; 4(15):1539-44. PubMed ID: 12505526 [TBL] [Abstract][Full Text] [Related]
29. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. Litwin V; Gumperz J; Parham P; Phillips JH; Lanier LL J Exp Med; 1993 Oct; 178(4):1321-36. PubMed ID: 8376937 [TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of human and mouse natural killer tumor recognition using retroviral antisense in primary natural killer cells: involvement with MHC class I killer cell inhibitory receptors. Ortaldo JR; Mason AT; Mason LH; Winkler-Pickett RT; Gosselin P; Anderson SK J Immunol; 1997 Feb; 158(3):1262-7. PubMed ID: 9013968 [TBL] [Abstract][Full Text] [Related]
31. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155 [TBL] [Abstract][Full Text] [Related]
32. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Rouas-Freiss N; Marchal RE; Kirszenbaum M; Dausset J; Carosella ED Proc Natl Acad Sci U S A; 1997 May; 94(10):5249-54. PubMed ID: 9144223 [TBL] [Abstract][Full Text] [Related]
33. The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). Keller MD; Chen DF; Condron SA; Liu N; Reinsmoen NL; Buckley RH J Clin Immunol; 2007 Jan; 27(1):109-16. PubMed ID: 17191149 [TBL] [Abstract][Full Text] [Related]
34. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. Pende D; Biassoni R; Cantoni C; Verdiani S; Falco M; di Donato C; Accame L; Bottino C; Moretta A; Moretta L J Exp Med; 1996 Aug; 184(2):505-18. PubMed ID: 8760804 [TBL] [Abstract][Full Text] [Related]
35. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. Gumperz JE; Litwin V; Phillips JH; Lanier LL; Parham P J Exp Med; 1995 Mar; 181(3):1133-44. PubMed ID: 7532677 [TBL] [Abstract][Full Text] [Related]
36. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Poggi A; Tomasello E; Revello V; Nanni L; Costa P; Moretta L Int Immunol; 1997 Sep; 9(9):1271-9. PubMed ID: 9310830 [TBL] [Abstract][Full Text] [Related]
37. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443 [TBL] [Abstract][Full Text] [Related]
38. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Verheyden S; Schots R; Duquet W; Demanet C Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456 [TBL] [Abstract][Full Text] [Related]
39. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Aversa F; Tabilio A; Terenzi A; Velardi A; Falzetti F; Giannoni C; Iacucci R; Zei T; Martelli MP; Gambelunghe C Blood; 1994 Dec; 84(11):3948-55. PubMed ID: 7524753 [TBL] [Abstract][Full Text] [Related]